18Dec 2017

A PHARMACOECONOMIC STUDY AND ITS APPRAISAL IN IMPROVING HEALTH CARE OUTCOMES IN PATIENTS SUFFERING FROM TYPE-2 DIABETES AMONG RURAL AREAS IN SOUTH-EAST INDIA.

  • Pharm.Dintern, Department of Pharmacy Practice, Chalapathi Institute of Pharmaceutical Sciences, Guntur.
  • Associate Professor, Department of Pharmacy Practice, Chalapathi Institute of Pharmaceutical Sciences, Guntur.
  • Principal, Chalapathi Institute of Pharmaceutical Sciences, Guntur.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Type 2 diabetes mellitus is a chronic metabolic disease which is a major problem in India, resulting not only in significant direct medical costs but also indirect productivity losses due to disability and early mortality. Objectives: Main objective was to assess the health care cost and to provide health related counselling on Type 2 Diabetes, to assess the medication adherence, to educate patients regarding importance of medication adherence on their disease condition. Methodology: A prospective observational cohort household study was conducted near the villages of the capital Amaravathi, Andhra Pradesh. The collected sample size was 392 Type -2 diabetic patients. Patient data as well as cost details were collected from the patients for a period of 6 months. The data was analyzed to determine the average treatment cost for diabetes. Medication adherence was assessed using MMAS-8 scale. Patients were educated by clinical pharmacists and follow up was taken. The healthcare outcomes were measured from the medication adherence of the patients. Results: A sample size of n=392 Type-2 diabetic patients were obtained. Cost utility analysis was performed and the mean cost per month for the drugs used by 392 patients was 4614.68 rupees. Majority of the patients were using Metformin+Glimepiride combination. In monotherapy Metformin was mostly commonly used. The medication adherence was assessed in type-2 diabetes and conducted a follow up after educating the patient and got a significant p value of 0.003. Conclusion: Economic status of the patient should be considered while prescribing. Due to the cost of medication maximum number of the patients were unable to bear the cost. This is indirectly decreasing the medication adherence which is further increasing the complexity of disease. In addition to that it is increasing the economic burden on the individual due to complications.

  1. Rascati KL. Essentials of Pharmacoeconomics. Philadelphia (USA): Lippincott Williams & Wilkins; 2009.
  2. Tom Walley, Alan Haycox, Angela Boland, Pharmacoeconomics, Churchill Livingstone Title ISBN: 978-0-443-07240-6
  3. Talwalkar PG.7. Practical Diabetes Mellitus, 5th ed. Mumbai, India. 2017. Available from: https://www.practo.com/mumbai/doctor/dr-pradeep-talwalkar accessed on March 2017
  4. Schmitz P, Martin KJ, Miller DD. Internal Medicine Just the Facts. New York: McGraw Hill Companies; 2008.
  5. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy A Pathophysiologic Approach, 7th Ed. New York: McGraw Hill Companies; 2008.
  6. Shah JV, Patni KN, Deshpande SS. Achieving Glycemic Control of Diabetic Patients through Clinical Pharmacist Provided Counseling. Journal of Pharmaceutical Science and Bioscientific Research 2015; 5(4): 322-327.
  7. Ettaro L, The economic burden of diabetes, Pharmaeconomics, 2004, 22, p. 149-164
  8. Hoerger T, Segel J, Gregg E, Saaddine J. Is Glycemic Control Improving in U.S. Adults?. Diabetes Care. 2007;31(1):81-86.
  9. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030: Response to Rathman and Giani. Diabetes Care. 2004;27(10):2569-2570.
  10. Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care. 2003;26(3):917-932.
  11. Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
  12. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology. 2001;48(5):643-648.
  13. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al., The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1993;329(14):977-986.
  14. Clarke P, Gray A, Briggs A, Stevens R, Matthews D, Holman R. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48(5):868-877.
  15. Ettaro L, Songer T, Zhang P, Engelgau M. Cost-of-Illness Studies in Diabetes Mellitus. PharmacoEconomics. 2004;22(3):149-164.
  16. Segel JE. Cost-of-Illness Studies?A Primer. RTI-UNC Center of Excellence in Health Promotion Economics; 2006.
  17. Budget 2017: What it means for the healthcare sector | Forbes India Blog. Forbes?India.?2017.?Available?from: http://www.forbesindia.com/blog/economy-policy/budget-2017-what-it-means-for-the-healthcare-sector/
  18. Mateti U, Kunduru B, Akari S. Health-care cost of diabetes in South India: A cost of illness study. Journal of Research in Pharmacy Practice. 2013;2(3):114.
  19. Suleiman,?et?al.,??A.Suleiman,?O.?F.?Fadeke?and?O.?Okubanjo, Pharmacoeconomic Evaluation of Anti-Diabetic Therapy in A Nigerian Tertiary Health Institution, ; 2006; vol.(5): 132 ? 137
  20. Acharya L, Rau N, Udupa N, Rajan M, Vijayanarayana K. Assessment of cost of illness for diabetic patients in South Indian tertiary care hospital. Journal of Pharmacy AndBioallied Sciences. 2016;8(4):314.
  21. Fu A, Qiu Y, Radican L, Wells B. Health Care and Productivity Costs Associated With Diabetic Patients With Macrovascular Comorbid Conditions. Diabetes Care. 2009;32(12):2187-2192.

[K. Satya Durga, N. Sowmya, S. Charishma, P. Sharmila Nirojini and Ramarao Nadendla. (2017); A PHARMACOECONOMIC STUDY AND ITS APPRAISAL IN IMPROVING HEALTH CARE OUTCOMES IN PATIENTS SUFFERING FROM TYPE-2 DIABETES AMONG RURAL AREAS IN SOUTH-EAST INDIA. Int. J. of Adv. Res. 5 (Dec). 890-901] (ISSN 2320-5407). www.journalijar.com

K.Satya Durga
Department of Pharmacy Practice, Chalapathi Institute of Pharmaceutical Sciences, Guntur

DOI:

Article DOI: 10.21474/IJAR01/6035      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6035

Download Full Paper

Download PDF No. of Downloads: 23 | No. of Views: 89